Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. PIMA548001

Invitrogen™ Oxelumab Recombinant Human Monoclonal Antibody (R4930 (Oxelumab))
GREENER_CHOICE

Catalog No. PIMA548001
Change view
Click to view available options
Quantity:
200 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA548001 200 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PIMA548001 Supplier Invitrogen™ Supplier No. MA548001
Only null left
Add to Cart
Edge
Add to Cart

Description

Human Recombinant Monoclonal Antibody

Specificity: Binds to human OX40L.

Oxelumab is a biosimilar that targets TNFSF4.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Oxelumab
Applications Flow Cytometry, Inhibition Assays
Classification Recombinant Monoclonal
Clone R4930 (Oxelumab)
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation PBS with 0.02% ProClin 300
Gene Alias huMAb OX40L; R4930; RG4930; RO4989991
Host Species Human
Immunogen Oxelumab binds to human OX40L, the ligand of OX40, stimulatory receptor that is expressed on activated T cells, natural killer (NK) cells and natural killer T (NKT) cells.
Purification Method Protein A
Quantity 200 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Human
Content And Storage Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Product Type Antibody
Form Liquid
Isotype IgG1 κ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.